Xiao Liu

Xiao Liu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2025 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
HZHuan Zhang
Huan Zhang
SDShuo Ding
Shuo Ding
HXHuai Xue
Huai Xue
SWShuguang Wang
Shuguang Wang
XQXiaoyu Quan
Xiaoyu Quan
HTHai Tang
Hai Tang
Bone defects caused by trauma, tumor resection, and surgery present significant clinical challenges, often resulting in complications such as delayed union, nonunion, and even long-term functional impairment. Current treatments, including autografts and allografts, are limited by donor site morbidity, immune rejection, and pathogen transmission, highlighting the need for developing reliable synthetic alternatives. To address these challenges, we report a binary composite hydrogel combining gelatin methacryloyl (GelMA) and κ-Carrageenan, reinforced with calcium phosphate cements (CPC). GelMA ensures rapid gelation and biocompatibility, κ-carrageenan improves injectability, and CPC enhances mechanical strength and osteogenic activity, collectively creating a robust and versatile hydrogel system. Furthermore, the hydrogel’s injectable, adaptive, and self-healing characteristics enable it to conform to irregular bone defect sites, providing mechanical support and osteogenic stimulation. It also releases bioactive components to accelerate bone regeneration. With exceptional toughness and resilience, this hydrogel recovers its shape after deformation, positioning it as a promising candidate for clinical bone defect repair applications.

21 February 2023 in Frontiers in Pediatrics
Verified
Journal Article
Open access
ZXZhiyuan Xu
Zhiyuan Xu
HLHaonan Liu
Haonan Liu
SZShuaishuai Zhou
Shuaishuai Zhou
TCTiancheng Chen
Tiancheng Chen
CMChao Meng
Chao Meng
XLXiao Liu
Xiao Liu
Objectives: To analyze the trends in mortality and causes of death among children under 5 years of age in Xuzhou, China between 2016 and 2020, in order to protect children's health and provide a basis for formulating child survival, development, and protection strategies.Methods: A population-based epidemiological study was conducted. Data were obtained from the Xuzhou Center for Disease Control Prevention. We input the data into the excel database and analyzed with SPSS20.0.Results: There were 1,949 children under 5 years of age died in Xuzhou, The number of deaths from 2016 to 2020 were 573 (29.40%), 577 (29.60%), 371 (19.04%), 334 (17.14%), and 94 (4.82%) respectively, mortality in children showed a downward trend. The number of deaths was relatively high in January (195 cases, 10.01%), February (190 cases, 9.75%), and May (180 cases, 9.24%), while was relatively small in July (147 cases, 7.54%), August (139 cases, 7.13%), and September (118 cases, 6.05%). The leading causes of death (COD) in children under 5 years of age were neonatal suffocation and hypoxia (323 cases, 16.57%). Pizhou (528 cases, 27.09%) showed the highest number of deaths in children under 5 years of age in China, and the Kaifa (25 cases, 1.28%) zone showed the lowest death toll.Conclusions: Our research suggested that the current strategies for reducing child mortality should prioritize the actions on neonatal deaths and conduct targeted interventions for the main cause.

3 February 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
ZXZhiyuan Xu
Zhiyuan Xu
XLXiao Liu
Xiao Liu
LZLiang Zhang
Liang Zhang
XYXianliang Yan
Xianliang Yan
Objectives: Acute respiratory distress syndrome (ARDS) is associated with high rates of morbidity and mortality. However, the evidence regarding the effectiveness of commonly used treatments, including corticosteroids, neuromuscular blocking agents (NMBAs), and inhaled nitric oxide (iNO), remains uncertain. Therefore, this study aimed to compare and rank these three treatments to identify the most effective option.Data sources: We searched PubMed, Embase, Cochrane Library, and Web of Science for clinical trials from the earliest records to 1 May 2024.Study selection and data extraction: Clinical trials evaluating three interventions compared with the control group for ARDS were included, with restrictions on any language. Data were extracted by two independent reviewers. Frequentist network meta-analysis (NMA) was performed to identify the most effective intervention, and treatments were ranked using the surface under the cumulative ranking (SUCRA) curve. The primary outcome was 28-day mortality, while secondary outcomes included ventilator-free days up to 28 days, ICU mortality, in-hospital mortality, and the incidence of new infection events.Data synthesis: Data from 26 clinical trials encompassing 5,071 patients were analyzed. Vecuronium bromide was the most effective strategy for reducing 28-day mortality compared to conventional treatment, iNO, methylprednisolone, and placebo (OR 0.38, 95% CI 0.15–1.00, and OR 0.30, 95% CI 0.10–0.85 and OR 0.25, 95% CI 0.08–0.74 and OR 0.23, 95% CI 0.08–0.65; SUCRA: 96.6%). Dexamethasone was identified as the most effective treatment option for increasing ventilator-free days at 28 days compared to conventional therapy and cisatracurium (MD 3.60, 95% CI 1.77–5.43, and MD 3.40, 95% CI 0.87–5.92; SUCRA: 93.2%). Methylprednisolone demonstrated the highest effectiveness for preventing ICU mortality (SUCRA: 88.5%). Although dexamethasone, cisatracurium, conventional therapy, methylprednisolone, and iNO treatment did not show significant superiority in reducing in-hospital mortality, dexamethasone showed the highest probability of being the most effective treatment option (SUCRA: 79.7%). Furthermore, dexamethasone treatment showed the highest safety in reducing the incidence of new infection events compared with placebo and iNO (OR 0.61, 95% CI 0.42–0.88, and OR 0.33, 95% CI 0.19–0.58; SUCRA: 91.8%).Conclusion: This NMA suggests that corticosteroids may provide benefits to patients with ARDS. While the application of NMBAs may reduce 28-day mortality, iNO did not demonstrate a significant beneficial effect as a therapeutic measure.Systematic review registration: PROSPERO, CRD42022333165 https://www.crd.york.ac.uk/PROSPERO/.

23 February 2026 in Langenbeck's Archives of Surgery
Verified
Journal Article
Open access
PDF file
SFShuo Feng
Shuo Feng
HYHeng-Heng Yu
Heng-Heng Yu
LWLi Wang
Li Wang
JWJiaChuan Wu
JiaChuan Wu
SQShang Qiu
Shang Qiu
XLXiao Liu
Xiao Liu
Objective To identify risk factors for fixation failure, avascular necrosis (AVN), and nonunion after reduction and internal fixation of femoral neck fractures in adults. Methods This single-center retrospective study included 217 adult patients who underwent reduction and internal fixation for femoral neck fractures between January 2012 and December 2023. Demographic variables, comorbidities, smoking status, excessive alcohol consumption, mechanism of injury, fracture type, time interval from injury to operation, fixation method, reduction quality, and implant removal were extracted from medical records. Outcomes (fixation failure, AVN, and nonunion) were ascertained during follow-up. Multivariable logistic regression was used to identify factors associated with each outcome. Results Among 217 patients, fixation failure occurred in 24.0% (n = 52), AVN in 14.3% (n = 31), and nonunion in 9.7% (n = 21). Fixation failure was associated with displaced fracture pattern (Garden III/IV) (OR = 3.314, P = 0.007), poor reduction quality (OR = 2.571, P = 0.036), and excessive alcohol consumption (OR = 3.510, P = 0.010). AVN was associated with excessive alcohol consumption (OR = 5.603, P = 0.002), Garden III/IV fractures (OR = 3.802, P = 0.023), and poor reduction quality (OR = 4.020, P = 0.006). Cannulated screw fixation (OR = 0.255, P = 0.014) and earlier surgery (≤ 1 day: OR = 0.100, P = 0.006; 1–3 days: OR = 0.307, P = 0.028) were associated with lower odds of nonunion. Conclusion In adult femoral neck fractures treated with internal fixation, fracture displacement, poor reduction quality, and excessive alcohol consumption were independently associated with fixation failure and avascular necrosis. Earlier surgery was associated with reduced odds of nonunion. Cannulated screw fixation was also associated with lower odds of nonunion versus other methods, although residual confounding cannot be excluded. These findings highlight the importance of optimizing reduction quality and addressing modifiable risk factors to improve outcomes. Levels of Evidence Level III

1 January 2025 in Advances in Interventional Cardiology
Verified
Journal Article
Open access
XLXiao Liu
Xiao Liu
LXLele Xiao
Lele Xiao
HLHaoyang Liu
Haoyang Liu
JWJie Wang
Jie Wang
WWWentian Wang
Wentian Wang
ZZZhengzheng Zhang
Zhengzheng Zhang
Introduction: Hypertension (HTN) poses a significant health threat in China, increasing the risk of cardiovascular disease. However, the impact of self-management interventions on patients with HTN in China has yet to be thoroughly explored. Methods: This review examines the impact of...

7 February 2023 in Research Square
Verified
Preprint
Open access
PDF file
ZXZhiyuan Xu
Zhiyuan Xu
HLHaonan Liu
Haonan Liu
SZShuaishuai Zhou
Shuaishuai Zhou
RZRuiqi Zhang
Ruiqi Zhang
CMChao Meng
Chao Meng
XYXianliang Yan
Xianliang Yan
OBJECTIVES: Acute respiratory distress syndrome (ARDS) is linked to high rates of morbidity and mortality. Evidence examining commonly used corticosteroids, neuromuscular blocking agents (NMBAs) and inhaled nitric oxide (iNO) remains uncertain. The aim of the study was to compare and rank these three treatments to identify the best one. DATA SOURCES: We searched Pubmed, Embase, Cochrane Library, and Web of Science from the earliest records to May 1, 2022 for clinic trials. STUDY SELECTIONT AND DATA EXTRACTION: Clinical trials of three interventions compared with control group for ARDS, no language restricted. Data were extracted by 2 independent reviewers. Frequentist network meta-analyses (NMA) were performed to identify the best intervention and treatments were ranked using the surface under the cumulative ranking (SUCRA) curve. Primary outcome was 28-day mortality. Secondary outcomes varied ventilator-free days at 28 days, ICU mortality, In-hospital mortality and new infection events. DATA SYNTHESIS: Data were combined from 26 clinical trials which included 5071 patients. Vecuronium bromide was the best strategy to reduce 28-day mortality compared with the conventional treatment, iNO, methylprednisolone and placebo (OR 0.38, 95% CI 0.15-1.00 and OR 0.30, 95% CI 0.10-0.85 and OR 0.25, 95% CI 0.08-0.74 and OR 0.23, 95% CI 0.08-0.65; SUCRA: 96.6%). Dexamethasone was the best treatment option for increasing ventilator-free days at 28 days compared to conventional therapy and cisatracurium (MD 3.60, 95% CI 1.77-5.43 and MD 3.40, 95% CI 0.87-5.92; SUCRA: 93.2%). Methylprednisolone was the most effective treatment option to prevent ICU mortality (SUCRA: 88.5%). Though dexamethasone, cisatracurium, conventional therapy, methylprednisolone and iNO treatment showed no significant superiority of in-hospital mortality protection over placebo, suggesting that it had the highest probability of being the best treatment option (SUCRA: 79.7%) for reducing in-hospital mortality. Dexamethasone treatment showed the highest safety for decreasing the incidence of new infection events compared with placebo and iNO (OR 0.61, 95% CI 0.42-0.88 and OR 0.33, 95% CI 0.19-0.58; SUCRA: 91.8%). Conclusions: This NMA suggested that corticosteroids are possibly beneficial in the patients with ARDS while application of NMBAs may reduce 28-day mortality, iNO as a therapeutic measure which did not show a prominent beneficial effect. Study registration:PROSPERO, CRD42022333165